Moreover, zebrafish models of metabolic disorders, such as obesity and diabetes, have been used to investigate the therapeutic potential of AMPK activators to improve glucose homeostasis and lipid metabolism (Ghaddar and Diotel, 2022; Gut et al., 2017; Wiggenhauser and Kroll, 2018). Here, PRKAA1 is linked to metabolic disease.